Aurora Cannabis

What Aurora Cannabis does

Aurora Cannabis (NASDAQ: ACB) is a Canadian-headquartered global medical cannabis company that cultivates, manufactures, and distributes pharmaceutical-grade cannabis products across regulated international markets including Germany, Australia, Poland, the United Kingdom, Canada, and New Zealand. The company operates EU-GMP and TGA-GMP certified manufacturing facilities in Canada, with a recently acquired 59,000 sq ft EU-GMP indoor cultivation site in Ontario (Safari Flower Company, April 2026). Its technology foundation rests on proprietary cannabis genetics — Farm Gas, Driftwood Diesel, Sourdough, and Black Jelly — protected under Canadian Plant Breeders' Rights and EU Community Plant Variety Rights, developed at the Aurora Coast R&D facility in Comox, British Columbia. Ongoing R&D includes a powdery mildew resistance genetic marker (PM2) program with the University of British Columbia, funded by Genome British Columbia.

The company sells dried flower, pre-rolls, resin cartridges, and pastilles under multiple brands including Aurora, MedReleaf, CraftPlant, Whistler Cannabis Co., IndiMed, and the recently launched German-market Daily Special. Distribution is achieved through named pharmacy and B2B partnerships: Leafio/Montu Australia servicing 4,000+ pharmacies, Vitura Health's Canview platform covering ~4,700 Australian pharmacies, and direct pharmacy plus telemedicine channels in Germany. In March 2026 Aurora announced a strategic pivot to medical cannabis only, exiting Canadian adult-use to concentrate on higher-margin regulated international markets. Manufacturing is augmented by a white-label agreement with Bioxyne/Breathe Life Sciences producing GMP-certified oils and vapes across multiple international markets.

For FY2026, Aurora reported record total net revenue of $320.6 million with medical cannabis contributing $288.6 million (81% of revenue, 95% of adjusted gross profit), international medical cannabis up 33% year-over-year, and record adjusted EBITDA of $53.8 million (up 32% YoY). The company is debt-free with $154.4 million in cash and holds a US$100 million ATM equity facility earmarked for further capacity expansion and M&A. Approximately 1,100 employees support operations across six countries under CEO Miguel Martin, who has led the company since September 2020 and additionally serves as Executive Chairman.

Name

Aurora Cannabis

Legal name

Aurora Cannabis Enterprises Inc.

Website

https://auroramj.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aurora Cannabis is a Canadian global medical cannabis producer selling EU-GMP certified proprietary dried flower, pre-rolls, resin cartridges, and pastilles across Germany, Australia, Poland, UK, Canada, and New Zealand through pharmacy and telemedicine distribution.

Ownership category

akta.pro rank

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Cannabis Product Sales: Aurora generates revenue primarily through the sale of medical cannabis products including dried flower, pre-rolls, resin cartridges, and pastilles across international markets including Germany, Australia, Poland, UK, Canada, and New Zealand. Medical cannabis represents 81% of total revenue and 95% of adjusted gross profit.
2. Consumer Cannabis Products: The company previously sold recreational cannabis products but is strategically exiting this lower-margin segment to focus on medical cannabis operations.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Aurora Cannabis is a Canadian-based global medical cannabis company that cultivates, manufactures, and distributes pharmaceutical-grade cannabis products (dried flower, pre-rolls, resin cartridges, and pastilles) across regulated international markets including Germany, Australia, Poland, UK, Canada, and New Zealand. The company operates EU-GMP and TGA-GMP certified manufacturing facilities in Canada and develops proprietary cannabis cultivars protected by Canadian Plant Breeders' Rights and EU Community Plant Variety Rights.

Product overview

Aurora Cannabis is a global medical cannabis company that has pivoted to focus solely on medical cannabis operations, exiting the adult-use recreational market. The company operates a multi-brand portfolio anchored by the Aurora® medical cannabis brand, supplemented by sub-brands including Daily Special™ (affordable German market brand), MedReleaf (Australian medical brand), and CraftPlant. The product portfolio consists of proprietary cannabis cultivars (Farm Gas™, Driftwood Diesel™, Sourdough™, Black Jelly) offered as dried flower, pre-rolls, pastilles, and resin cartridges, all manufactured at EU-GMP and TGA-GMP certified facilities in Canada and Germany. Products are distributed across key international markets including Germany, Poland, UK, Australia, Canada, and New Zealand.

Differentiator

Problem solved

Functional benefit

Brands

• Daily Special™: Medical cannabis flower brand launched in Germany in December 2025, featuring sativa-dominant cultivars with 21-23% THC content at accessible price points.
• San Raf Pink OG Kush
• Electric Honeydew
• Chemango Kush
• Black Jelly
• Farm Gas™
• Driftwood Diesel™

Products and services

• Aurora Medical Cannabis Brand Core medical cannabis brand offering proprietary cannabis cultivars including dried flower, pre-rolls, pastilles, and resin cartridges distributed across regulated international medical markets.
• Daily Special Affordable medical cannabis brand launched in Germany in December 2025, featuring sativa-dominant cultivars with 21-23% THC content available through pharmacies and telemedicine platforms.
• MedReleaf Medical cannabis brand available through MedReleaf Australia subsidiary, offering products distributed across over 4,000 pharmacies in Australia.
• CraftPlant Craft cannabis brand distributed through MedReleaf Australia's pharmacy network of over 4,000 locations nationwide.
• Cannabis flos Aurora Medical cannabis flower product line featuring proprietary cultivars distributed across European markets including Germany and Poland.
• Farm Gas Proprietary cannabis cultivar (SOT20R07-007) with exclusive rights granted through Canadian Plant Breeders' Rights and EU Community Plant Variety Rights, available to medical patients in Germany, Poland, UK, Canada, and Australia.
• Driftwood Diesel Proprietary cannabis cultivar (SOT20R07-005) developed at Aurora Coast R&D facility in Comox, British Columbia, covered under Canadian Plant Breeders' Rights with exclusive rights to grow, propagate, and sell finished products.
• Sourdough Proprietary cannabis cultivar (ACB21T044) granted EU Community Plant Variety Rights, providing Aurora exclusive commercial control across all 27 EU member states.
• Black Jelly High-potency proprietary medical cannabis cultivar with 27% THC content, launched in Poland in December 2025 as part of the Cannabis flos Aurora brand portfolio.
• Australia and New Zealand Medical Portfolio Expansion Multi-product portfolio expansion in Australia and New Zealand markets featuring THC dried flower products for New Zealand and resin cartridges for Australia, manufactured at EU-GMP and TGA-GMP certified Canadian facilities.
• Global Medical Cannabis Portfolio Expansion Global multi-market expansion of medical cannabis portfolio including dried flower, pre-rolls, and pastilles across Canada, Germany, Poland, and Australia, leveraging GMP-certified manufacturing network.

Quantifiable outcome

• Record annual global medical cannabis net revenue of $288.6 million in FY2026, up 18% year-over-year
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Safari Flower CompanycoreStrategic or Co-development Partner · 15 April 2026Acquisition of Safari Flower Company for aggregate consideration of $26.5 million, consisting of $15 million cash payment and issuance of 2,417,180 common shares, with additional $2 million contingent on certain conditions. Safari operates a 59,000 square foot EU GMP-certified indoor cultivation and manufacturing facility in Ontario, Canada.
• Bioxyne/Breathe Life SciencescoreTechnology or Integration · 31 March 2026Manufacturing agreement for GMP-certified medicinal cannabis oils for the Australian market with first deliveries already completed. The partnership expands into GMP-manufactured cannabis vapes for Australia, UK, and Germany, moving Bioxyne into Aurora's global supply chain. Breathe Life Sciences has produced over 5,000 sublingual oil products and 20,000 vape units for Aurora.
• Vitura HealthcoreChannel Partner/ Reseller/ Distributor · 17 March 2026Commercial distribution agreement making MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview online platform, distributed through the Burleigh Heads Cannabis nationwide network. Vitura estimates the deal could contribute up to $15 million in additional annual revenue. Canview platform represents approximately 4,700 Australian pharmacies.
• Leafio/Montu AustraliacoreChannel Partner/ Reseller/ Distributor · 2 December 2025Distribution partnership where Leafio's wholesale division will distribute Aurora's medical cannabis brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed through its nationwide supply chain servicing over 4,000 pharmacies. The partnership aims to enhance clinician education, product innovation, and improve patient outcomes.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Tilray Brands: Tilray Brands is a Canadian-headquartered global cannabis operator with significant medical cannabis distribution in Germany, Australia, and other international markets. Closely comparable to Aurora in product mix (dried flower, oils, vapes), target channels (pharmacies and direct-to-patient), and footprint across EU and Oceania.
• Canopy Growth Corporation: Canopy Growth is a major Canadian licensed producer with established German medical cannabis operations (Canopy Health Germany) and EU-GMP certified supply. Comparable to Aurora across medical cannabis category, German market exposure, and pharmaceutical-grade positioning.
• OrganiGram Holdings: OrganiGram is a Canadian medical cannabis producer with international expansion (Germany, Australia, UK) and notably stronger EBITDA margins than Aurora. Direct peer in target customer (medical patients via pharmacies), product format (dried flower and concentrates), and regulatory compliance approach.
• Cronos Group: Cronos Group is a Canadian licensed producer with international medical cannabis distribution including Israel and Germany via partnerships. Direct peer in cannabis producer profile, GMP-certified manufacturing, and cross-border medical distribution model.
• Village Farms International: Village Farms International operates cannabis operations under the Pure Sunfarms brand in Canada and is expanding into international medical markets. Comparable to Aurora as a Canadian-headquartered licensed producer pursuing selective international medical growth.
• SNDL Inc. (formerly Sundial Growers): SNDL is a Canadian cannabis producer and retailer with a portfolio of cultivation, processing, and retail assets. Direct peer in Canadian licensed producer profile with international growth ambitions, though more consumer-market exposed than Aurora's current medical-only focus.

Broad incumbents

• Jazz Pharmaceuticals (GW Pharma): Jazz Pharmaceuticals acquired GW Pharmaceuticals and markets Epidiolex, a CBD-based FDA-approved prescription drug. Comparable to Aurora's pharmaceutical-grade cannabis positioning but operates at a much larger scale as a broad specialty pharma incumbent with cannabis as one therapeutic area.
• Curaleaf Holdings: Curaleaf is one of the largest US multi-state cannabis operators with limited international exposure. Comparable as a vertically integrated cannabis producer-distributor, but operates predominantly in US state-legal adult-use and medical markets rather than Aurora's international medical focus.
• Trulieve Cannabis: Trulieve is a US-focused vertically integrated cannabis operator with significant wholesale and retail operations. Comparable in vertical integration and pharmaceutical-grade aspirations but limited overlap with Aurora's international medical cannabis footprint.

Emerging players

• Demetra Brands (formerly IMC Inc.): Demetra/IMC is a Ukraine- and Germany-focused medical cannabis producer with EU-GMP operations and German distribution. Comparable to Aurora's EU-GMP certified model and German medical cannabis focus, but with a more regionally concentrated footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/aurora_mmj
• LinkedInlinkedin.com/company/aurora-cannabis-inc-
• Facebookfacebook.com/auroramedical.ca

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds12 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A17 records

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Cannabis